Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE The recent finding of overexpression of the polycomb group transcriptional repressor EZH2 in prostate cancer raises the possibility that transcriptional regulation at the chromatin level may play a role in the development of the metastatic phenotype and suggests new avenues of exploration with respect to patient stratification and therapeutics. 12450788 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression. 12374981 2002
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. 14500907 2003
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer. 15184867 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Ezh2 levels are increasingly elevated during prostate cancer progression. 15684044 2005
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 GeneticVariation disease BEFREE Moreover, our results suggest that genetic variations of the EZH2 gene are not responsible for the linkage of 7q to aggressive prostate cancer. 16015586 2005
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Our goal was to evaluate the gene copy number and expression alterations of EZH2 in prostate cancer. 16575874 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE EZH2 expression increases during prostate cancer progression, whereas BMI-1 and SIRT1 are not well investigated. 18637271 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE EZH2 mRNA expression density in the metastatic prostate cancer group was significantly higher than in the control (p=0.023) and localized prostate cancer groups (p=0.019). 18159594 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease CTD_human Integrative molecular concept modeling of prostate cancer progression. 17173048 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease CTD_human Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. 17003774 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE EZH2 promotes proliferation and invasion of prostate cancer cells, which can account for the correlation between EZH2 expression levels and an adverse prostate cancer prognosis. 17252556 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Essential for embryonic development, the polycomb group protein enhancer of zeste homolog 2 (EZH2) is overexpressed in breast and prostate cancers and is implicated in the growth and aggression of the tumors. 17502350 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE The protein EZH2 is overexpressed in disseminated prostate cancer, implicating a role of PcG complexes in tumor progression. 17134822 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Cytoplasmic EZH2 expression levels correlate with nuclear EZH2 expression in prostate cancer samples. 18095286 2008
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase polycomb group (PcG) protein, which has been implicated in the process of cellular differentiation and cancer progression for both breast and prostate cancer. 17453341 2008
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2) occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma multiforme (GBM). 19934320 2009
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Overexpression of EZH2 protein has been associated with biological malignancy of prostate cancer and several other cancers. 18619895 2009
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 AlteredExpression disease BEFREE Increased expression of the transcriptional repressor EZH2 has been reported to be associated with poor prognosis in various malignancies including breast cancer and prostate cancer. 19901851 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE Using an Affymetrix cDNA microarray analysis, we investigated the expression of MSMB, CRISP3, androgen receptor (AR), KLK3 and Enhancer of Zeste Homologue-2 (EZH2) in tissue from prostate cancer patients receiving (n=17) or not receiving (n=23) ADT before radical prostatectomy. 20680031 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE By using multiple cell lines, and examining overexpression and knockdown of EZH2 concurrently, a broad view of EZH2's role in prostate cancer was achieved. 20087897 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE Since Ezh2 is overexpressed and acts as an oncogene in PCa, it has been proposed as a bona fide target of PCa therapy. 20478051 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. 20622896 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 PosttranslationalModification disease BEFREE ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. 20479932 2010
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.400 Biomarker disease BEFREE These results link two major pathways in prostate cancer by providing two additional and complementary Myc-regulated mechanisms by which EZH2 upregulation occurs and is enforced during prostatic carcinogenesis. 21941025 2011